Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

@article{Komrokji2015ResultsOA,
  title={Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.},
  author={Rami S. Komrokji and John Francis Seymour and Andrew W. Roberts and Martha Wadleigh and Luen Bik To and Robyn Scherber and Elyce Turba and Andrew Dorr and Joy Zhu and Lixia Wang and Tanya Granston and Mary S. Campbell and Ruben A Mesa},
  journal={Blood},
  year={2015},
  volume={125 17},
  pages={
          2649-55
        }
}
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2 study further characterized the safety and efficacy of pacritinib in the treatment of patients with MF. Eligible patients had clinical splenomegaly poorly controlled with standard therapies or were… 
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
TLDR
The study suggests that pacritinib has unique characteristics, namely a lack of substantial myelosuppression and manageable side effects, making it an attractive target for further evaluation in MF.
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
TLDR
In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.
Clinical potential of pacritinib in the treatment of myelofibrosis
TLDR
Pacritinib, a JAK2 and FMS-like tyrosine kinase 3 (FLT3) inhibitor, has shown promising results in early phase trials with limited myelotoxicity and clinical responses that are comparable with those seen with ruxolitinib in MF, even in patients with severe thrombocytopenia.
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
TLDR
It is demonstrated that ruxolitinib has promising activity in CMML with particular benefit in those with disease-related B symptoms that warrants further study.
Pacritinib: a new agent for the management of myelofibrosis?
TLDR
Pacritinib appears to be an effective agent for the control of MF-related symptoms and splenomegaly with potentially fewer haematological side-effects when compared with ruxolitinib and seems a particularly promising agent for anaemic and thrombocytopenic patients.
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis
TLDR
Dysregulation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been described in myelofibrosis and pacritinib, a selective JAK2/FLT3 inhibitor has shown promising results, without significant thrombocytopenia.
Ruxolitinib for the Treatment of Essential Thrombocythemia
TLDR
The role of Ruxolitinib in patients refractory or intolerant to hydroxycarbamide and the goal of therapy with the use of JAK inhibitor therapy in ET needs to be defined carefully and is explored within this timely review article.
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives
TLDR
The role of JAKi in the modern management of patients with MPN is critically discussed, with almost 50% lose response by three years and dose-dependent toxicities may lead to suboptimal dosing or treatment discontinuation.
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
TLDR
Evidence of tolerability and a potential therapeutic activity of momelotinib for subjects that support further evaluation in ongoing, phase 3 randomized trials are provided.
...
...

References

SHOWING 1-10 OF 24 REFERENCES
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
TLDR
Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
  • A. Younes, J. Romaguera, Joy Zhu
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
SB1518 has encouraging activity in relapsed lymphoma, providing the first proof-of-principle of the potential therapeutic value of targeting the JAK/STAT pathway in lymphoma in the clinical setting.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
TLDR
Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
TLDR
In a mouse model of JAK2V617F(+) MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppression effects.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
TLDR
An international panel of experts recently convened and delineated 3 response categories: complete remission (CR), partial remission (PR), and clinical improvement (CI).
Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.
TLDR
SB1518 was well tolerated at doses up to 500 mg daily in advanced patients with MF and AML, and shows promising clinical activity in MF patients with splenomegaly, and is being evaluated in subjects with acute and chronic myeloid diseases in a Phase I dose escalation study.
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
TLDR
Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages and a high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
Advances in the management of myelofibrosis.
TLDR
Significant advances have been made in understanding the pathophysiology of MF, leading to novel therapeutic approaches, including ruxolitinib, the first JAK1/2 inhibitor approved by the Food and Drug Administration for the treatment of patients with intermediate- or high-risk MF.
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
TLDR
In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
...
...